Oculis Holding AG Ordinary shares (OCS) - Total Liabilities
Based on the latest financial reports, Oculis Holding AG Ordinary shares (OCS) has total liabilities worth $39.94 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Oculis Holding AG Ordinary shares - Total Liabilities Trend (2020–2025)
This chart illustrates how Oculis Holding AG Ordinary shares's total liabilities have evolved over time, based on quarterly financial data. See Oculis Holding AG Ordinary shares (OCS) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Oculis Holding AG Ordinary shares Competitors by Total Liabilities
The table below lists competitors of Oculis Holding AG Ordinary shares ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
DongHua Testing Technology Co Ltd
SHE:300354
|
China | CN¥105.22 Million |
|
Keystone Technology Co Ltd
SHG:605588
|
China | CN¥1.91 Billion |
|
FRoSTA AG
F:NLM
|
Germany | €217.82 Million |
|
Synergie SE
PA:SDG
|
France | €817.63 Million |
|
BES Engineering Co
TW:2515
|
Taiwan | NT$43.56 Billion |
|
TPG RE Finance Trust Inc
NYSE:TRTX
|
USA | $2.98 Billion |
|
Hippo Holdings Inc
NYSE:HIPO
|
USA | $1.61 Billion |
|
Maxic Technology Inc. A
SHG:688458
|
China | CN¥258.02 Million |
Liability Composition Analysis (2020–2025)
This chart breaks down Oculis Holding AG Ordinary shares's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Oculis Holding AG Ordinary shares market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.96 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.17 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Oculis Holding AG Ordinary shares's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Oculis Holding AG Ordinary shares (2020–2025)
The table below shows the annual total liabilities of Oculis Holding AG Ordinary shares from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $39.94 Million | -14.97% |
| 2024-12-31 | $46.97 Million | +127.73% |
| 2023-12-31 | $20.62 Million | -84.73% |
| 2022-12-31 | $135.05 Million | +13.49% |
| 2021-12-31 | $119.00 Million | +98.21% |
| 2020-12-31 | $60.04 Million | -- |
About Oculis Holding AG Ordinary shares
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candida… Read more